NICE draft RA recommendations leave "little hope for patients"
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, today published draft recommendations saying that rheumatoid arthritis (RA) patients should only be prescribed a second TNF-inhibitor as part of clinical research.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.